NOVAVAX INC NVAX
Nasdaq · XNAS · stock
Chart by TradingView
4/9
Piotroski F — financial health
-7.28
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.1B | $440.3M | — | — | -$127.8M |
| 2024 | $682.2M | -$187.5M | — | — | -$623.8M |
| 2023 | $983.7M | -$545.1M | — | — | -$716.9M |
| 2022 | $2.0B | -$657.9M | — | — | -$634.1M |
| 2021 | $1.1B | -$1.7B | — | — | -$351.7M |
| 2020 | $475.6M | -$418.3M | — | — | $627.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Rodgers Richard J | director | 2026-06-20 | Option exercise | 18,880 | — |
| King Rachel K. | director | 2026-06-20 | Option exercise | 18,880 | — |
| DOUGLAS RICHARD | director | 2026-06-20 | Option exercise | 18,880 | — |
| MCGLYNN MARGARET G | director | 2026-06-20 | Option exercise | 18,880 | — |
| MOTT DAVID M | director | 2026-06-20 | Option exercise | 18,880 | — |
| Alton Gregg H | director | 2026-06-20 | Option exercise | 18,880 | — |
| Newton Charles W. | director | 2026-04-25 | Option exercise | 9,520 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -7.28 (distress)
- Working capital / assets 0.441
- Retained earnings / assets -3.883
- EBIT / assets 0.385
- Equity / liabilities -0.098
Source: SEC EDGAR filings · CIK 0001000694 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.